Regeneron appoints Christopher Fenimore as CFO to succeed retiring Robert Landry

REGENERON PHARMACEUTICALS, INC.

Christopher Fenimore promoted to SVP, Finance and CFO; effective day after 2023 10-K filing (expected Feb 5, 2024).
Jason Pitofsky promoted to VP, Controller; no change in compensation.
Fenimore's base salary increased to $660,000; granted equity award with target fair value of $5,000,000.
Equity award includes options for 8,499 shares (4-year vest) and 2,370 RSUs (50% at years 2 and 4).
Succession plan previously disclosed; Landry retiring.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Robert E. Landry

Chief Financial Officer

REGN · REGENERON PHARMACEUTICALS, INC.

Effective: 2024-02-06
Successor: Christopher Fenimore
Filed: January 31, 2024, 6:59 PM ET

the current Chief Financial Officer, Robert E. Landry, who is retiring.

Appointed

Christopher Fenimore

Senior Vice President, Finance and Chief Financial Officer

REGN · REGENERON PHARMACEUTICALS, INC.

Effective: 2024-02-06
Filed: January 31, 2024, 6:59 PM ET

appointed Christopher Fenimore, currently the Company’s Senior Vice President, Controller, as Senior Vice President, Finance and Chief Financial Officer

Appointed

Jason Pitofsky

Vice President, Controller

REGN · REGENERON PHARMACEUTICALS, INC.

Effective: 2024-02-06
Filed: January 31, 2024, 6:59 PM ET

appointed Jason Pitofsky, currently the Company’s Vice President, Accounting and Financial Reporting, as Vice President, Controller.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Robert E. Landry departed as Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..

Action: retiring
Role: Chief Financial Officer

Exact text from the filing

the current Chief Financial Officer, Robert E. Landry, who is retiring.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Fenimore was appointed as Senior Vice President, Finance and Chief Financial Officer at REGENERON PHARMACEUTICALS, INC..

Action: appointed
Role: Senior Vice President, Finance and Chief Financial Officer

Exact text from the filing

appointed Christopher Fenimore, currently the Company’s Senior Vice President, Controller, as Senior Vice President, Finance and Chief Financial Officer

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason Pitofsky was appointed as Vice President, Controller at REGENERON PHARMACEUTICALS, INC..

Action: appointed
Role: Vice President, Controller

Exact text from the filing

appointed Jason Pitofsky, currently the Company’s Vice President, Accounting and Financial Reporting, as Vice President, Controller.

View on SEC.gov

REGENERON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-008807

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.